BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35056060)

  • 1. Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor.
    Pardridge WM
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor.
    Pardridge WM; Chou T
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34205013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
    Pardridge WM
    Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
    Boado RJ; Zhang Y; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.
    Pardridge WM; Boado RJ; Patrick DJ; Ka-Wai Hui E; Lu JZ
    Mol Pharm; 2018 Nov; 15(11):5207-5216. PubMed ID: 30226787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport.
    Boado RJ
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.
    Boado RJ; Pardridge WM
    Drug Metab Dispos; 2009 Dec; 37(12):2299-304. PubMed ID: 19741036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
    Pardridge WM
    BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
    Zhou QH; Boado RJ; Pardridge WM
    J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.
    Pardridge WM
    Adv Drug Deliv Rev; 2022 May; 184():114234. PubMed ID: 35307484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor.
    Zhang Y; Pardridge WM
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1075-81. PubMed ID: 15718287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardized Preclinical
    Morrison JI; Petrovic A; Metzendorf NG; Rofo F; Yilmaz CU; Stenler S; Laudon H; Hultqvist G
    Mol Pharm; 2023 Mar; 20(3):1564-1576. PubMed ID: 36808999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.
    Pardridge WM
    Front Drug Deliv; 2023; 3():. PubMed ID: 37583474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
    Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
    Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
    Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
    Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
    Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
    Boado RJ; Ka-Wai Hui E; Zhiqiang Lu J; Pardridge WM
    Biotechnol Bioeng; 2014 Nov; 111(11):2317-25. PubMed ID: 24889100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey.
    Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Mol Pharm; 2016 Sep; 13(9):3241-6. PubMed ID: 27513815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.